Two pain drugs used by millions will be combined in a single tablet

with inflammation, said Michelle Bateson, who oversees North America research and development at Kenvue, Tylenol’s parent company.

The combination was evaluated across eight clinical studies and demonstrated “superior pain relief” compared to the individual medications, Bateson said.

About 75% of persistent pain sufferers reported dissatisfaction with continue reading …